Noom Health's SmartRx program on track to cut employer's GLP-1 spend by nearly 80%.
Article excerpt
Noom Health's SmartRx program on track to cut employer's GLP-1 spend by nearly 80%. Apr 23, 2026 | Last updated Apr 23, 2026 Source references. Early data from first participating employer show that SmartRx can save organizations millions by bypassing traditional pbms to deliver brand-name GLP-1 medications. NEW YORK, April 23, 2026 - Noom Health, the enterprise division of the leading behavior change platform Noom, today announced that its Smart[Rx] program is on pace to cut GLP-1 medication costs by nearly 80% for its first participating employer, projecting approximately $1.3M in annual spend compared to $6.2M in the prior year. Program integration began in January 2026 with these early results pointing to a huge savings opportunity for other organizations grappling with runaway anti-obesity medication expenses. This data offers meaningful proof that a structured, clinically integrated GLP-1 strategy can deliver millions in real savings without compromising access or member outcomes.* Employer health strategies have traditionally centered on condition-specific programs to manage diseases like obesity, diabetes, and cardiovascular conditions individually, which has led to employers managing multiple point solutions simultaneously, often with low coordination, engagement, and return on investment. GLP-1 medications have rapidly accelerated this challenge, becoming one...
Keep reading with a free account
The rest of this article, and every signal for Noom, is in your free account.
Extracted from this sentence
Noom Health developed its Metabolic Suite offering to address this integration opportunity.
